Thursday, 27 May 2010

DermaPet




DermaPet may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for DermaPet



Dioctyl Sulfosuccinic Acid

Dioctyl Sulfosuccinic Acid sodium salt (a derivative of Dioctyl Sulfosuccinic Acid) is reported as an ingredient of DermaPet in the following countries:


  • Australia

Urea

Urea peroxyde (a derivative of Urea) is reported as an ingredient of DermaPet in the following countries:


  • Australia

International Drug Name Search

Monday, 24 May 2010

Fluostérol




Fluostérol may be available in the countries listed below.


Ingredient matches for Fluostérol



Colecalciferol

Colecalciferol is reported as an ingredient of Fluostérol in the following countries:


  • France

Sodium Fluoride

Sodium Fluoride is reported as an ingredient of Fluostérol in the following countries:


  • France

International Drug Name Search

Sugast




Sugast may be available in the countries listed below.


Ingredient matches for Sugast



Sucralfate

Sucralfate is reported as an ingredient of Sugast in the following countries:


  • Italy

International Drug Name Search

Thursday, 20 May 2010

Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets


Pronunciation: dex-brome-fen-IR-a-meen/dex-troe-meth-OR-fan/fen-ill-EF-rin
Generic Name: Dexbrompheniramine/Dextromethorphan/Phenylephrine
Brand Name: Tussal-ER and Y-Cof DM


Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets are used for:

Relieving symptoms of sinus congestion, runny nose, sneezing, and cough due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.


Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets are a decongestant, antihistamine, and cough suppressant combination. It works by constricting blood vessels and reducing swelling in the nasal passages, The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing while the cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.


Do NOT use Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets if:


  • you are allergic to any ingredient in Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets

  • you have severe high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

  • you are unable to urinate or are having an asthma attack

  • you take sodium oxybate (GHB) or you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets:


Some medical conditions may interact with Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a fast, slow, or irregular heartbeat

  • if you have a history of adrenal gland problems (eg, adrenal gland tumor); heart problems; high blood pressure; diabetes; heart blood vessel problems; stroke; glaucoma; a blockage of your bladder, stomach, or intestines; ulcers; trouble urinating; an enlarged prostate or other prostate problems; seizures; or an overactive thyroid

  • if you have a history of asthma, chronic cough, lung problems (eg, chronic bronchitis, emphysema), or chronic obstructive pulmonary disease (COPD), or if your cough occurs with large amounts of mucus

Some MEDICINES MAY INTERACT with Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, MAO inhibitors (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because side effects of Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets may be increased

  • Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

  • Bromocriptine or hydantoins (eg, phenytoin) because side effects may be increased by Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because effectiveness may be decreased by Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets:


Use Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets may be taken with or without food.

  • Swallow Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets whole. Do not break, crush, or chew before swallowing.

  • If you miss a dose of Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets.



Important safety information:


  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets may cause dizziness, drowsiness, or blurred vision. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets. Using Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • Do not take diet or appetite control medicines while you are taking Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets without checking with your doctor.

  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets contains dexbrompheniramine, dextromethorphan, and phenylephrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains dexbrompheniramine, dextromethorphan, or phenylephrine. If it does or if you are uncertain, contact your doctor or pharmacist.

  • Do NOT exceed the recommended dose or take Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets for longer than prescribed without checking with your doctor.

  • If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.

  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets may cause increased sensitivity to the sun. Avoid exposure to the sun, sunlamps, or tanning booths until you know how you react to Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets. Use a sunscreen or protective clothing if you must be outside for a prolonged period.

  • If you are scheduled for allergy skin testing, do not take Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets for several days before the test because it may decrease your response to the skin tests.

  • Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets.

  • Use Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets with caution in the ELDERLY because they may be more sensitive to its effects.

  • Caution is advised when using Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets in CHILDREN because they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets, discuss with your doctor the benefits and risks of using Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets during pregnancy. It is unknown if Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets are excreted in breast milk. Do not breast-feed while taking Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets.


Possible side effects of Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Dexbrompheniramine/Dextromethorphan/Phenylephrine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.


Proper storage of Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets:

Store Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets out of the reach of children and away from pets.


General information:


  • If you have any questions about Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.

  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dexbrompheniramine/Dextromethorphan/Phenylephrine Sustained-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dexbrompheniramine/Dextromethorphan/Phenylephrine resources


  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Side Effects (in more detail)
  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Use in Pregnancy & Breastfeeding
  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Drug Interactions
  • Dexbrompheniramine/Dextromethorphan/Phenylephrine Support Group
  • 0 Reviews for Dexbrompheniramine/Dextromethorphan/Phenylephrine - Add your own review/rating


Compare Dexbrompheniramine/Dextromethorphan/Phenylephrine with other medications


  • Cough and Nasal Congestion

Tuesday, 18 May 2010

Lamotor




Lamotor may be available in the countries listed below.


Ingredient matches for Lamotor



Lamotrigine

Lamotrigine is reported as an ingredient of Lamotor in the following countries:


  • Vietnam

International Drug Name Search

Mulchina




Mulchina may be available in the countries listed below.


Ingredient matches for Mulchina



Pranoprofen

Pranoprofen is reported as an ingredient of Mulchina in the following countries:


  • Japan

International Drug Name Search

Monday, 17 May 2010

Alfacalcidolo




Alfacalcidolo may be available in the countries listed below.


Ingredient matches for Alfacalcidolo



Alfacalcidol

Alfacalcidolo (DCIT) is also known as Alfacalcidol (Rec.INN)

International Drug Name Search

Glossary

DCITDenominazione Comune Italiana
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, 16 May 2010

Vitamina B1 Angelini




Vitamina B1 Angelini may be available in the countries listed below.


Ingredient matches for Vitamina B1 Angelini



Thiamine

Thiamine hydrochloride (a derivative of Thiamine) is reported as an ingredient of Vitamina B1 Angelini in the following countries:


  • Italy

International Drug Name Search

Friday, 14 May 2010

Woundcare Powder




Woundcare Powder may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Woundcare Powder



Cetrimide

Cetrimide is reported as an ingredient of Woundcare Powder in the following countries:


  • United Kingdom

International Drug Name Search

Wednesday, 5 May 2010

Nystamysyn Farmasyn




Nystamysyn Farmasyn may be available in the countries listed below.


Ingredient matches for Nystamysyn Farmasyn



Nystatin

Nystatin is reported as an ingredient of Nystamysyn Farmasyn in the following countries:


  • Greece

International Drug Name Search

Tuesday, 4 May 2010

DiltaHexal




DiltaHexal may be available in the countries listed below.


Ingredient matches for DiltaHexal



Diltiazem

Diltiazem is reported as an ingredient of DiltaHexal in the following countries:


  • Luxembourg

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of DiltaHexal in the following countries:


  • Australia

  • Germany

International Drug Name Search

Aspoxicillin




Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0063358-49-6

Chemical Formula

C21-H27-N5-O7-S

Molecular Weight

493

Therapeutic Category

Antibacterial: Penicillin, penicillinase-sensitive

Chemical Name

(2S,5R,6R)-6-[(2R)-2-[(2R)-2-Amino-3-(methylcarbamoyl)propionamidol]-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid

Foreign Names

  • Aspoxicillinum (Latin)
  • Aspoxicillin (German)
  • Aspoxicilline (French)
  • Aspoxicillina (Spanish)

Generic Names

  • TA 058 (IS: Tanabe)
  • Aspoxicillin (PH: JP XIV)

Brand Name

  • Doyle
    Sawai Seiyaku, Japan

International Drug Name Search

Glossary

ISInofficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Monday, 3 May 2010

Calcitonin Target




Calcitonin Target may be available in the countries listed below.


Ingredient matches for Calcitonin Target



Calcitonin

Calcitonin is reported as an ingredient of Calcitonin Target in the following countries:


  • Greece

International Drug Name Search

Sunday, 2 May 2010

Clonidine HCl Sandoz




Clonidine HCl Sandoz may be available in the countries listed below.


Ingredient matches for Clonidine HCl Sandoz



Clonidine

Clonidine hydrochloride (a derivative of Clonidine) is reported as an ingredient of Clonidine HCl Sandoz in the following countries:


  • Netherlands

International Drug Name Search

Ficard




Ficard may be available in the countries listed below.


Ingredient matches for Ficard



Nifedipine

Nifedipine is reported as an ingredient of Ficard in the following countries:


  • Bangladesh

International Drug Name Search